We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice.
- Authors
Benjamin Ory; Marie‐Françoise Heymann; Akira Kamijo; François Gouin; Dominique Heymann; Françoise Redini
- Abstract
Although there is no doubt that bisphosphonates (BPs), specific inhibitors of osteoclasts, are beneficial for the treatment of bone metastases, their effects on visceral metastases are unclear. The effect of zoledronic acid (ZOL) was examined in vivo on lung metastasis progression and animal survival, and in vitro on the cellular mechanisms involved.An animal model of lung metastasis was developed in C3H/He mice inoculated intravenously with a spontaneous murine osteosarcoma POS‐1 cell line. Lung metastasis was determined at the time of autopsy. ZOL was assessed in vitro on POS‐1 cell proliferation, cell cycle progression, and caspase‐1 and ‐3 activities.The overall survival in five independent experiments (two series treated with ZOL 0.1 mg/kg twice a week, and three series with 0.1 mg/kg five times a week) showed a significant increase of the actuarial survival: 0.422 ± 0.07 in ZOL‐treated animals versus 0.167 ± 0.07 in controls (P = 0.036). Lung metastases were absent in all ZOL‐treated mice that survived more than 21 days postinjection as revealed by macroscopic and histologic analysis. In vitro, a 48‐hour incubation with 10 μM ZOL inhibited POS‐1 cell line proliferation associated with cell cycle arrest in S‐phase. In addition, ZOL induced a weak increase of caspase‐3 activity, but not caspase‐1.We demonstrate that ZOL exerts a direct antitumor effect on POS‐1 cells in vitro, significantly diminishes osteosarcoma‐induced lung metastasis in vivo, thereby prolonging survival of POS‐1‐inoculated animals. Cancer 2005. © 2005 American Cancer Society.
- Publication
Cancer (0008543X), 2005, Vol 104, Issue 11, p2522
- ISSN
0008-543X
- Publication type
Article